NASDAQ:CYAN

Cyanotech Competitors

$3.14

+0.05 (+1.62 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$3.06

Now: $3.14▼

$3.14

50-Day Range

$3.09

MA: $3.57▼

$4.14

52-Week Range

$2.02

Now: $3.14▼

$6.29

Volume34,892 shs

Average Volume253,480 shs

Market Capitalization$19.14 million

P/E Ratio31.40

Dividend YieldN/A

Beta0.4

Cyanotech (NASDAQ:CYAN) Vs. CGC, APHA, CRON, TLRY, USNA, and ACB

Should you be buying CYAN stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Cyanotech, including Canopy Growth (CGC), Aphria (APHA), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), and Aurora Cannabis (ACB).

Cyanotech vs. Canopy Growth Stock

Canopy Growth (NASDAQ:CGC) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Earnings and Valuation

This table compares Canopy Growth and Cyanotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$297.34 million	35.73	$-993,370,000.00	$1.32	21.06
Cyanotech	$31.90 million	0.60	$390,000.00	N/A	N/A

Cyanotech has lower revenue, but higher earnings than Canopy Growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Canopy Growth and Cyanotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	5	10	2	1	1.94
Cyanotech	0	0	0	0	N/A

Canopy Growth presently has a consensus price target of $35.6778, suggesting a potential upside of 28.34%. Given Canopy Growth's higher probable upside, equities research analysts clearly believe Canopy Growth is more favorable than Cyanotech.

Volatility and Risk

Canopy Growth has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares Canopy Growth and Cyanotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-312.84%	-13.11%	-9.66%
Cyanotech	1.82%	3.67%	1.80%

Insider and Institutional Ownership

10.2% of Canopy Growth shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 0.3% of Canopy Growth shares are owned by insiders. Comparatively, 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Cyanotech beats Canopy Growth on 7 of the 13 factors compared between the two stocks.

Cyanotech vs. Aphria Stock

Aphria (NASDAQ:APHA) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Volatility and Risk

Aphria has a beta of 2.67, indicating that its share price is 167% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Earnings and Valuation

This table compares Aphria and Cyanotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aphria	$405.96 million	11.03	$-63,210,000.00	($0.06)	-235.67
Cyanotech	$31.90 million	0.60	$390,000.00	N/A	N/A

Cyanotech has lower revenue, but higher earnings than Aphria.

Insider and Institutional Ownership

10.3% of Aphria shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aphria and Cyanotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aphria	0	5	3	0	2.38
Cyanotech	0	0	0	0	N/A

Aphria presently has a consensus price target of $22.00, suggesting a potential upside of 55.59%. Given Aphria's higher probable upside, equities research analysts clearly believe Aphria is more favorable than Cyanotech.

Profitability

This table compares Aphria and Cyanotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aphria	-36.10%	-2.30%	-1.66%
Cyanotech	1.82%	3.67%	1.80%

Summary

Cyanotech beats Aphria on 7 of the 12 factors compared between the two stocks.

Cyanotech vs. Cronos Group Stock

Cronos Group (NASDAQ:CRON) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility and Risk

Cronos Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cronos Group and Cyanotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$25.64 million	117.46	$1.17 billion	$0.67	12.48
Cyanotech	$31.90 million	0.60	$390,000.00	N/A	N/A

Cronos Group has higher earnings, but lower revenue than Cyanotech.

Insider & Institutional Ownership

11.8% of Cronos Group shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by insiders. Comparatively, 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Cronos Group and Cyanotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	2	4	1	0	1.86
Cyanotech	0	0	0	0	N/A

Cronos Group presently has a consensus price target of $8.75, suggesting a potential upside of 4.67%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Cyanotech.

Profitability

This table compares Cronos Group and Cyanotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cronos Group	266.31%	-1.61%	-1.41%
Cyanotech	1.82%	3.67%	1.80%

Summary

Cronos Group beats Cyanotech on 8 of the 12 factors compared between the two stocks.

Cyanotech vs. Tilray Stock

Tilray (NASDAQ:TLRY) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility and Risk

Tilray has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Valuation and Earnings

This table compares Tilray and Cyanotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray	$166.98 million	17.69	$-321,170,000.00	($1.69)	-10.18
Cyanotech	$31.90 million	0.60	$390,000.00	N/A	N/A

Cyanotech has lower revenue, but higher earnings than Tilray.

Insider & Institutional Ownership

12.6% of Tilray shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 16.8% of Tilray shares are owned by insiders. Comparatively, 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Tilray and Cyanotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray	1	9	0	0	1.90
Cyanotech	0	0	0	0	N/A

Tilray presently has a consensus price target of $18.3078, suggesting a potential upside of 6.44%. Given Tilray's higher probable upside, analysts plainly believe Tilray is more favorable than Cyanotech.

Profitability

This table compares Tilray and Cyanotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tilray	-242.60%	-92.70%	-20.70%
Cyanotech	1.82%	3.67%	1.80%

Summary

Cyanotech beats Tilray on 6 of the 11 factors compared between the two stocks.

Cyanotech vs. USANA Health Sciences Stock

USANA Health Sciences (NYSE:USNA) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility and Risk

USANA Health Sciences has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Valuation and Earnings

This table compares USANA Health Sciences and Cyanotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
USANA Health Sciences	$1.06 billion	1.92	$100.53 million	$4.41	22.42
Cyanotech	$31.90 million	0.60	$390,000.00	N/A	N/A

USANA Health Sciences has higher revenue and earnings than Cyanotech.

Insider & Institutional Ownership

54.1% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 45.4% of USANA Health Sciences shares are owned by insiders. Comparatively, 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for USANA Health Sciences and Cyanotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
USANA Health Sciences	0	0	2	0	3.00
Cyanotech	0	0	0	0	N/A

USANA Health Sciences presently has a consensus price target of $126.00, suggesting a potential upside of 27.41%. Given USANA Health Sciences' higher probable upside, analysts plainly believe USANA Health Sciences is more favorable than Cyanotech.

Profitability

This table compares USANA Health Sciences and Cyanotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
USANA Health Sciences	10.57%	32.91%	22.26%
Cyanotech	1.82%	3.67%	1.80%

Summary

USANA Health Sciences beats Cyanotech on 11 of the 12 factors compared between the two stocks.

Cyanotech vs. Aurora Cannabis Stock

Aurora Cannabis (NYSE:ACB) and Cyanotech (NASDAQ:CYAN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Aurora Cannabis and Cyanotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	6	9	0	0	1.60
Cyanotech	0	0	0	0	N/A

Aurora Cannabis presently has a consensus price target of $10.9264, suggesting a potential upside of 38.66%. Given Aurora Cannabis' higher probable upside, analysts plainly believe Aurora Cannabis is more favorable than Cyanotech.

Volatility and Risk

Aurora Cannabis has a beta of 3.44, indicating that its stock price is 244% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Insider & Institutional Ownership

11.9% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 11.3% of Cyanotech shares are owned by institutional investors. 26.2% of Cyanotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Aurora Cannabis and Cyanotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-1,238.94%	-16.32%	-13.12%
Cyanotech	1.82%	3.67%	1.80%

Valuation and Earnings

This table compares Aurora Cannabis and Cyanotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$207.89 million	7.50	$-2,468,190,000.00	($2.86)	-2.76
Cyanotech	$31.90 million	0.60	$390,000.00	N/A	N/A

Cyanotech has lower revenue, but higher earnings than Aurora Cannabis.

Summary

Cyanotech beats Aurora Cannabis on 6 of the 11 factors compared between the two stocks.